Jaguar Animal Health (JAGX) Set to Post Earnings on Thursday

Jaguar Animal Health (NASDAQ:JAGX) is anticipated to release its Q3 2026 resultson Thursday, November 12th. Analysts expect Jaguar Animal Health to announce earnings of ($444.2941) per share and revenue of $4.85 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Jaguar Animal Health (NASDAQ:JAGX) last issued its earnings results on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($782.25) by $766.55. The business had revenue of $1.23 million for the quarter, compared to the consensus estimate of $4.24 million.

Jaguar Animal Health Price Performance

Shares of JAGX opened at $0.44 on Tuesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.40 and a current ratio of 0.69. The company has a 50 day moving average price of $4.94 and a 200-day moving average price of $109.22. Jaguar Animal Health has a fifty-two week low of $0.36 and a fifty-two week high of $1,039.50. The stock has a market capitalization of $850,395.00, a PE ratio of -0.00 and a beta of -0.09.

Wall Street Analyst Weigh In

A number of brokerages recently commented on JAGX. Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Thursday, October 15th. Wall Street Zen upgraded Jaguar Animal Health to a “sell” rating in a research note on Saturday, October 10th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has an average rating of “Sell”.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a commercial-stage animal health company focused on developing and commercializing plant-based pharmaceuticals for gastrointestinal disorders in animals. Its research programs are designed to address conditions affecting companion animals, livestock and other animal species, with an emphasis on therapies that support intestinal function and overall animal health.

The company’s lead product is Canalevia-CA1, a prescription product containing crofelemer. Canalevia-CA1 received conditional approval from the U.S.